1.00
-0.29(-22.48%)
Currency In USD
Previous Close | 1.29 |
Open | 1.25 |
Day High | 1.25 |
Day Low | 1 |
52-Week High | 3.87 |
52-Week Low | 0 |
Volume | 2,964 |
Average Volume | 1,764 |
Market Cap | 12.99M |
PE | 2.94 |
EPS | 0.34 |
Moving Average 50 Days | 2.89 |
Moving Average 200 Days | 2.12 |
Change | -0.29 |
If you invested $1000 in Eagle Pharmaceuticals, Inc. (EGRX) 10 years ago, it would be worth $15.35 as of October 21, 2025 at a share price of $1. Whereas If you bought $1000 worth of Eagle Pharmaceuticals, Inc. (EGRX) shares 5 years ago, it would be worth $21.52 as of October 21, 2025 at a share price of $1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders
GlobeNewswire Inc.
53 minutes ago
WOODCLIFF LAKE, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the voting results for each of the matters presented at the Company’s 2025 annual meeting of stock
Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements
GlobeNewswire Inc.
Oct 15, 2025 8:30 PM GMT
WOODCLIFF LAKE, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three and six months ended June 30, 2025, are a
Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements
GlobeNewswire Inc.
Oct 06, 2025 11:30 PM GMT
WOODCLIFF LAKE, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three months ended March 31, 2025, are availabl